Dear Editor
In a letter to the editor in a recent issue of Cell Death and Differentiation, Abdel-Rahman et al1. reported the absence of mutations in the death pathways gene Fas (Apo-1/CD95) in colorectal carcinomas.1 From the absence of mutations in 24 colon cancers, 12 of which were classified as replication error positive (RER+), Abdel-Rahman et al1. concluded that such mutations confer no substantial growth advantage in colorectal carcinogenesis. In agreement with this report, we identified Fas mutations in only 10% of colon and gastric cancers of the microsatellite mutator phenotype (MMP), also denominated as RER or microsatellite instability (MSI). Mutations were also found in Apaf-1 and Bcl-10, two other genes involved in the cell death pathways. The mutations were detected in mononucleotide tracts within these three genes (Figure 1). The frequency of these frameshift mutations was low (Table 1) and they appeared to be heterozygous (Figure 2). However, considering the peculiar features of these tumors, we suggest that these frameshift mutations contribute to cancer progression by providing survival advantage.
The MMP pathway for gastrointestinal cancer presents two paradoxical features at first sight. First, despite accumulating hundreds of thousands of clonal somatic mutations in simple repeated sequences, these tumors exhibit a low mutation incidence in APC, K-ras and p532 prototypical cancer genes for colorectal carcinogenesis.3 Second, while ubiquitous mutations in non-functional poly (A)n sequences (such as the poly A tails of the Alu repeats), are biallelic,2 these tumors also accumulate many monoallelic (i.e. heterozygous) mutations in functional sequences, such as the coding regions of mutator (hMSH3, hMSH6),4 suppressor (p53, TGFβRII)2,5 and apoptotic (Bax)6 genes. In contrast, the manifestation of the tumor phenotype by cancers without the MMP is usually associated to the biallelic mutational inactivation of a few cancer genes such as APC and p53 tumor suppressors.3
The first paradox may be explained by the existence within some genes of simple repeats which are preferred targets for the MMP. Thus, in the presence of the mutator phenotype, mutations in these genes (i.e. Bax) occur sooner than in other genes of the same oncogenic (i.e. apoptotic) signaling pathways that do not have these repeats (i.e. p53).6 We propose here a model to explain the second paradox. Due to the exacerbated mutator phenotype of these tumors, their ability for escaping apoptosis may be facilitated by the accumulation of heterozygous mutations in multiple genes whose products play partially redundant and partially synergistic roles at different points of the apoptotic signaling network. This accumulation of heterozygous mutations presumably reduce the homeostatic threshold amount of the corresponding pro-apoptotic gene products.
In agreement with this hypothesis, most MMP+ tumors had frameshift mutations in more than one of these genes (Figure 2). Due to the still limited knowledge of the human genome and the strong mutator phenotype of these tumors, it appears very unlikely that these are the only death pathway genes mutated in cancer of the MMP. This accumulative haploinsufficiency model is not restricted to apoptotic pathways, but also applies to other networks involved in the homeostatic control of genome integrity and cell proliferation.
References
Abdel-Rahman WM et al. (1999) Cell Death Differ. 6: 387–388
Ionov Y et al. (1993) Nature 363: 558–561
Fearon E, Vogelstein B. . (1990) Cell 61: 759–767
Malkhosyan S et al. (1996) Nature 382: 499–500
Markowitz SD et al. (1995) Science 268: 1336–1338
Rampino N et al. (1997) Science 275: 967–969
Ashkenazi A, Dixit VM . (1998) Science 281: 1305–1308
Zou H et al. (1997) Cell 90: 405–413
Willis TG et al. (1999) Cell 96: 35–45
Soengas MS et al. (1999) Science 284: 156–159
Reed JC . (1999) Curr. Opin. Oncol. 11: 68–75
Yan M et al. (1999) J. Biol. Chem. 274: 10287–10292
Zhang Q et al. (1999) Nat. Genet. 22: 63–68
Lee SH et al. (1999) Oncogene 18: 3754–3760
Shin MS et al. (1999) Am. J. Pathol. 154: 1785–1791
Lee SH et al. (1999) Cancer Res. 59: 3068–3072
Dyer MJ . (1999) Br. J. Cancer 80: 1491
Hu Y et al. (1999) EMBO J. 18: 3586–3595
Yamamoto H et al. (1997) Cancer Res. 57: 4420–4426
Schwartz Jr S et al. (1999) Cancer Res. 59: 2995–3002
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yamamoto, H., Gil, J., Schwartz, S. et al. Frameshift mutations in Fas, Apaf-1, and Bcl-10 in gastro-intestinal cancer of the microsatellite mutator phenotype. Cell Death Differ 7, 238–239 (2000). https://doi.org/10.1038/sj.cdd.4400651
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cdd.4400651
This article is cited by
-
Effects of paclitaxel on permanent head and neck squamous cell carcinoma cell lines and identification of anti-apoptotic caspase 9b
Journal of Cancer Research and Clinical Oncology (2016)
-
Microsatellite instability: an update
Archives of Toxicology (2015)
-
Mutations in TGFbeta-RII and BAXmediate tumor progression in the later stages of colorectal cancer with microsatellite instability
BMC Cancer (2010)
-
Restoring TGFβ function in microsatellite unstable (MSI-H) colorectal cancer reduces tumourigenicity but increases metastasis formation
International Journal of Colorectal Disease (2009)
-
Frameshift mutations in coding repeats of protein tyrosine phosphatase genes in colorectal tumors with microsatellite instability
BMC Cancer (2008)